Product Code: GDHC497FP
Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of numerous targeted therapies, the field of SCLC has seen little advancement, and the standard of care (SOC) for several decades has been platinum-etoposide chemotherapy. Limited tumor tissue for translational research, poor understanding of the mechanisms underlying disease biology, and therapeutic resistance are major factors impeding the discovery of effective drugs, including targeted therapies in SCLC, proving a major clinical need for patients.
To date, there have been three targeted therapies approved to treat SCLC, Bristol-Myers Squibb's Opdivo (nivolumab), Roche's Tecentriq (atezolizumab), and Merck & Co.'s Keytruda (pembrolizumab) which were approved by the FDA in August 2018, March 2019 and June 2019, respectively. The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC. Following the approval of these new agents, relapsed/refractory patients are expected to have significantly improved therapeutic options. The increased prescription of branded therapies in treatment-naive and advanced patients will be the primary impetus driving the substantial growth in the SCLC market.
- There are 165 pipeline programs in active development for SCLC. What proportion of these products are first-in-class?
- How does first-in-class innovation vary by development stage and molecular target class?
- Which molecular target classes are prominently represented in the first-in-class SCLC pipeline?
- Which first-in-class targets have been identified as most promising for the treatment of SCLC?
- How does the distribution of target classes differ in terms of development stage?
- Across the SCLC landscape, there are 118 active companies. Which companies have formed partnerships?
- Which companies have first-in-class assets in development with no prior deal involvement?
Reasons to buy:
- Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. Visualize the composition of the SCLC market in terms of dominant molecule types and molecular targets.
- Analyze and compare the SCLC pipeline and stratify by stage of development, molecule type, and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class programs have been assessed and ranked according to their clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Recognize commercial opportunities by identifying first-in-class pipeline programs for SCLC that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SCLC programs.
1 Table of Contents
2 Small Cell Lung Cancer: Executive Summary
- 2.1 Pipeline Holds Some Potential for the Approval of More Targeted Therapies
- 2.2 High Levels of First-in-Class Innovation
- 2.3 Need for Disease-Modifying Pharmacotherapies
- 3.1 Catalyst
- 3.2 Related Reports
- 3.3 Upcoming Related Reports
4 Disease Overview
- 4.1 Etiology and Pathophysiology
- 4.2 Classification or Staging Systems
- 4.3 Sustained Innovation in SCLC
- 4.4 Epidemiology for SCLC
- 4.5 Overview for Marketed Products
5 Assessment of Pipeline Product Innovation
- 5.1 Overview
- 5.2 Pipeline by Stage of Development and Molecule Type
- 5.3 Pipeline by Molecular Target
- 5.4 Comparative Distribution of Programs Between SCLC Market and Pipeline by Therapeutic Target Family
- 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
- 5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
- 5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline
6 First-in-Class Molecular Target Evaluation
- 6.1 Overview
- 6.2 Pipeline Programs Targeting GTPase KRAS
- 6.3 Pipeline Programs Targeting Interleukin 2 Receptor Beta and Gamma
- 6.4 Pipeline Programs Targeting Heat Shock Protein 90
- 6.5 Pipeline Programs Targeting Serine/Threonine Protein Kinase AKT (AKT1, AKT2, AKT3)
- 6.6 Pipeline Programs Targeting Hepatitis A Virus Cellular Receptor 2
- 6.7 Pipeline Programs Targeting Serine/Threonine-Protein Kinase ATR
- 6.8 Pipeline Programs Targeting Protein Phosphatase 2A
- 6.9 Pipeline Programs Targeting Histone-lysine N-methyltransferase EZH2
- 6.10 Pipeline Programs Targeting Lymphocyte Activation Gene 3 Protein
7 Key Players and Deals
- 7.1 Overview
- 7.1.1 Allogene Therapeutics Enters into Licensing Agreement with Cellectis
- 7.1.2 Amgen and MD Anderson Enter Two Collaboration Agreements Across Various Cancer Types
- 7.1.3 MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center
- About GlobalData
- Contact Us
List of Tables
- Table 1: Definitions Used in TNM Classification and Clinical Staging System in Lung Cancer
- Table 2: AJCC Staging of Lung Cancer
- Table 3: SCLC Diagnosed Prevalent Cases (N), Thousands, 2014-2024
List of Figures
- Figure 1: SCLC, Global Market by Molecular Target and Molecule Type, 2019
- Figure 2: SCLC, Global, Pipeline by Stage of Development and Molecule Type, 2019
- Figure 3: SCLC, Global, Pipeline by Molecular Target and Stage of Development, 2019
- Figure 4: SCLC, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
- Figure 5: SCLC, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
- Figure 6: SCLC, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
- Figure 7: SCLC, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019